国际口腔医学杂志 ›› 2020, Vol. 47 ›› Issue (6): 669-676.doi: 10.7518/gjkq.2020088

• 综述 • 上一篇    下一篇

光动力疗法在口腔黏膜癌变防治中的应用

何宇晴(),但红霞(),陈谦明   

  1. 口腔疾病研究国家重点实验室 国家口腔疾病临床医学研究中心 口腔黏膜病国家临床重点专科 中国医学科学院口腔黏膜癌变与防治创新单元 四川大学华西口腔医院黏膜病科 成都 610041
  • 收稿日期:2019-11-14 修回日期:2020-06-02 出版日期:2020-11-01 发布日期:2020-11-06
  • 通讯作者: 但红霞
  • 作者简介:何宇晴,硕士,Email: 1193746389@qq.com
  • 基金资助:
    国家自然科学基金(81572663)

Application of photodynamic therapy for oral carcinogenesis prevention

He Yuqing(),Dan Hongxia(),Chen Qianming   

  1. State Key Laboratory of Oral Diseases & National Clinical Research Center for Oral Diseases & National Key Laboratory of Oral Mucosal Diseases & Innovation Unit of Oral Mucosal Carcinogenesis and Prevention, Chinese Academy of Medical Sciences & Dept. of Oral Medicine, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, China
  • Received:2019-11-14 Revised:2020-06-02 Online:2020-11-01 Published:2020-11-06
  • Contact: Hongxia Dan
  • Supported by:
    National Nature Science Foundation of China(81572663)

摘要:

口腔黏膜癌变是从正常口腔黏膜发展为口腔黏膜潜在恶性疾患,最终成为口腔癌的过程。通常的治疗目标是在癌变早期进行干预,防止癌变发生,但目前为止缺少疗效确切且安全的治疗方法。光动力疗法是一种基于光敏剂介导的光化学、光生物学反应,对病变细胞产生杀伤作用的治疗手段,在治疗疾病、改善预后等方面具有诸多优点,是口腔黏膜潜在恶性疾患及口腔鳞状细胞癌的一种新的治疗选择。本文主要对光动力疗法及其在口腔黏膜癌变防治中的应用进行综述。

关键词: 光动力疗法, 口腔黏膜潜在恶性疾患, 口腔鳞状细胞癌, 光敏剂

Abstract:

Oral carcinogenesis starts from the oral mucosa to oral potentially malignant disorder (OPMD) and eventually leads to oral cancer. Substantial effort has been directed to prevent oral carcinogenesis at its early stage; however, success is elusive. Photodynamic therapy is based on photosensitiser-mediated photochemical and photobiological effects leading to cellular damage in lesional tissues. This technique is a new treatment option for OPMD and oral squamous cell carcinoma. This article reviewed the application of photodynamic therapy for oral carcinogenesis prevention.

Key words: photodynamic therapy, oral potentially malignant disorders, oral squamous cell carcinoma, photosensitizer

中图分类号: 

  • R781.5
[1] Ganesh D, Sreenivasan P, Öhman J, et al. Potentially malignant oral disorders and cancer transformation[J]. Anticancer Res, 2018,38(6):3223-3229.
pmid: 29848669
[2] Mello FW, Miguel AFP, Dutra KL, et al. Prevalence of oral potentially malignant disorders: a systematic review and meta-analysis[J]. J Oral Pathol Med, 2018,47(7):633-640.
doi: 10.1111/jop.12726 pmid: 29738071
[3] Lodi G, Porter S. Management of potentially mali-gnant disorders: evidence and critique[J]. J Oral Pathol Med, 2007,37(2):63-69.
doi: 10.1111/j.1600-0714.2007.00575.x pmid: 18197849
[4] van der Waal I. Oral potentially malignant disorders: is malignant transformation predictable and preventable[J]. Med Oral Patol Oral Cir Bucal, 2014,19(4):e386-e390.
doi: 10.4317/medoral.20205 pmid: 24905952
[5] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018,68(6):394-424.
doi: 10.3322/caac.v68.6
[6] Sasahira T, Kirita T. Hallmarks of cancer-related newly prognostic factors of oral squamous cell carcinoma[J]. Int J Mol Sci, 2018,19(8):E2413.
pmid: 30115834
[7] Chi AC, Day TA, Neville BW. Oral cavity and oro-pharyngeal squamous cell carcinoma: an update[J]. CA Cancer J Clin, 2015,65(5):401-421.
pmid: 26215712
[8] Mroueh R, Haapaniemi A, Saarto T, et al. Non-cura-tive treatment of patients with oral tongue squamous-cell carcinoma[J]. Eur Arch Otorhinolaryngol, 2019,276(7):2039-2045.
doi: 10.1007/s00405-019-05456-y pmid: 31069467
[9] Sroussi HY, Epstein JB, Bensadoun RJ, et al. Common oral complications of head and neck cancer radiation therapy: mucositis, infections, saliva change, fibrosis, sensory dysfunctions, dental caries, periodontal disease, and osteoradionecrosis[J]. Cancer Med, 2017,6(12):2918-2931.
doi: 10.1002/cam4.1221 pmid: 29071801
[10] van Straten D, Mashayekhi V, de Bruijn HS, et al. Oncologic photodynamic therapy: basic principles, current clinical status and future directions[J]. Cancers (Basel), 2017,9(2):E19.
[11] Saini R, Lee NV, Liu KY, et al. Prospects in the ap-plication of photodynamic therapy in oral cancer and premalignant lesions[J]. Cancers (Basel), 2016,8(9):E83.
[12] Agostinis P, Berg K, Cengel KA, et al. Photodynamic therapy of cancer: an update[J]. CA Cancer J Clin, 2011,61(4):250-281.
doi: 10.3322/caac.20114 pmid: 21617154
[13] Tan IB, Dolivet G, Ceruse P, et al. Temoporfin-me-diated photodynamic therapy in patients with advanced, incurable head and neck cancer: a multicenter study[J]. Head Neck, 2010,32(12):1597-1604.
pmid: 20848401
[14] Figueira JA, Veltrini VC. Photodynamic therapy in oral potentially malignant disorders—critical litera-ture review of existing protocols[J]. Photodiagnosis Photodyn Ther, 2017,20:125-129.
doi: 10.1016/j.pdpdt.2017.09.007 pmid: 28918177
[15] Rak J, Pouckova P, Benes J, et al. Drug delivery sys-tems for phthalocyanines for photodynamic therapy[J]. Anticancer Res, 2019,39(7):3323-3339.
doi: 10.21873/anticanres.13475 pmid: 31262853
[16] Chen QM, Dan HX, Tang F, et al. Photodynamic the-rapy guidelines for the management of oral leuco-plakia[J]. Int J Oral Sci, 2019,11(2):14.
doi: 10.1038/s41368-019-0047-0 pmid: 30971683
[17] Zhao J, Duan L, Wang AH, et al. Insight into the efficiency of oxygen introduced photodynamic therapy (PDT) and deep PDT against cancers with various assembled nanocarriers[J]. Wiley Interdiscip Rev Nanomed Nanobiotechnol, 2020,12(1):e1583.
doi: 10.1002/wnan.1583 pmid: 31566931
[18] Lin HP, Chen HM, Yu CH, et al. Topical photody-namic therapy is very effective for oral verrucous hyperplasia and oral erythroleukoplakia[J]. J Oral Pathol Med, 2010,39(8):624-630.
pmid: 21054548
[19] Yu CH, Lin HP, Chen HM, et al. Comparison of clinical outcomes of oral erythroleukoplakia treated with photodynamic therapy using either light-emitting diode or laser light[J]. Lasers Surg Med, 2009,41(9):628-633.
doi: 10.1002/lsm.20841 pmid: 19816916
[20] Jin X, Xu H, Deng J, et al. Photodynamic therapy for oral potentially malignant disorders[J]. Photodia-gnosis Photodyn Ther, 2019,28:146-152.
[21] Henderson BW, Busch TM, Snyder JW. Fluence rate as a modulator of PDT mechanisms[J]. Lasers Surg Med, 2006,38(5):489-493.
pmid: 16615136
[22] Chen HM, Yu CH, Tu PC, et al. Successful treatment of oral verrucous hyperplasia and oral leukoplakia with topical 5-aminolevulinic acid-mediated photo-dynamic therapy[J]. Lasers Surg Med, 2005,37(2):114-122.
pmid: 16037967
[23] Warnakulasuriya S, Ariyawardana A. Malignant transformation of oral leukoplakia: a systematic review of observational studies[J]. J Oral Pathol Med, 2016,45(3):155-166.
[24] Lyu MY, Guo YS, Li S, et al. Hospital-based epi-demiological and clinical characterisation of the malignant transformation of oral leukoplakia in a Chinese population[J]. Int Dent J, 2017,67(4):252-259.
pmid: 28276054
[25] Maloth KN, Velpula N, Kodangal S, et al. Photody-namic therapy—a non-invasive treatment modality for precancerous lesions[J]. J Lasers Med Sci, 2016,7(1):30-36.
pmid: 27330695
[26] Han Y, Xu S, Jin JQ, et al. Primary clinical evaluation of photodynamic therapy with oral leukoplakia in Chinese patients[J]. Front Physiol, 2018,9:1911.
pmid: 30723421
[27] Selvam NP, Sadaksharam J, Singaravelu G, et al. Treatment of oral leukoplakia with photodynamic therapy: a pilot study[J]. J Cancer Res Ther, 2015,11(2):464-467.
pmid: 26148619
[28] Shafirstein G, Friedman A, Siegel E, et al. Using 5-aminolevulinic acid and pulsed dye laser for pho-todynamic treatment of oral leukoplakia[J]. Arch Otolaryngol Head Neck Surg, 2011,137(11):1117-1123.
doi: 10.1001/archoto.2011.178 pmid: 22106236
[29] Chen HM, Yu CH, Tsai T, et al. Topical 5-aminolevu-linic acid-mediated photodynamic therapy for oral verrucous hyperplasia, oral leukoplakia and oral erythroleukoplakia[J]. Photodiagnosis Photodyn Ther, 2007,4(1):44-52.
pmid: 25047191
[30] Li YT, Wang BJ, Zheng SW, et al. Photodynamic therapy in the treatment of oral leukoplakia: a syste-matic review[J]. Photodiagnosis Photodyn Ther, 2019,25:17-22.
pmid: 30391342
[31] Pietruska M, Sobaniec S, Bernaczyk P, et al. Clinical evaluation of photodynamic therapy efficacy in the treatment of oral leukoplakia[J]. Photodiagnosis Photodyn Ther, 2014,11(1):34-40.
pmid: 24211597
[32] Chen HM, Cheng SJ, Chiang. Topical photodynamic therapy is the first-line treatment of choice for oral erythroleukoplakia and oral verrucous hyperplasia[J]. J Formos Med Assoc, 2015,114(7):567-568.
pmid: 25937480
[33] Wong SJ, Campbell B, Massey B, et al. A phase Ⅰ trial of aminolevulinic acid-photodynamic therapy for treatment of oral leukoplakia[J]. Oral Oncol, 2013,49(9):970-976.
pmid: 23845699
[34] Prasanna SW, Ingle E, Aruna PR, et al. Photody-namic therapy of oral leukoplakia and oral lichen planus using methylene blue: a pilot study[J]. J Innov Opt Health Sci, 2015,8(1):1540005.
[35] Sulewska M, Duraj E, Sobaniec S, et al. A clinical evaluation of the efficacy of photodynamic therapy in the treatment of erosive oral lichen planus: a case series[J]. Photodiagnosis Photodyn Ther, 2017,18:12-19.
pmid: 28119140
[36] Bakhtiari S, Azari-Marhabi S, Mojahedi SM, et al. Comparing clinical effects of photodynamic therapy as a novel method with topical corticosteroid for treatment of oral lichen planus[J]. Photodiagnosis Photodyn Ther, 2017,20:159-164.
pmid: 28669793
[37] Mostafa D, Moussa E, Alnouaem M. Evaluation of photodynamic therapy in treatment of oral erosive lichen planus in comparison with topically applied corticosteroids[J]. Photodiagnosis Photodyn Ther, 2017,19:56-66.
doi: 10.1016/j.pdpdt.2017.04.014 pmid: 28450262
[38] Sulewska M, Duraj E, Sobaniec S, et al. A clinical evaluation of efficacy of photodynamic therapy in treatment of reticular oral lichen planus: a case series[J]. Photodiagnosis Photodyn Ther, 2019,25:50-57.
doi: 10.1016/j.pdpdt.2018.11.009 pmid: 30447415
[39] Rakesh N, Clint JB, Reddy SS, et al. Clinical eva-luation of photodynamic therapy for the treatment of refractory oral lichen planus—a case series[J]. Photodiagnosis Photodyn Ther, 2018,24:280-285.
doi: 10.1016/j.pdpdt.2018.09.011 pmid: 30261326
[40] Mirza S, Rehman N, Alrahlah A, et al. Efficacy of photodynamic therapy or low level laser therapy against steroid therapy in the treatment of erosive-atrophic oral lichen planus[J]. Photodiagnosis Photo-dyn Ther, 2018,21:404-408.
[41] Sobaniec S, Bernaczyk P, Pietruski J, et al. Clinical assessment of the efficacy of photodynamic therapy in the treatment of oral lichen planus[J]. Lasers Med Sci, 2013,28(1):311-316.
doi: 10.1007/s10103-012-1153-9 pmid: 22814895
[42] Schweitzer VG, Somers ML. PHOTOFRIN-media-ted photodynamic therapy for treatment of early stage (Tis-T2N0M0) SqCCa of oral cavity and oropharynx[J]. Lasers Surg Med, 2010,42(1):1-8.
doi: 10.1002/lsm.20881 pmid: 20077493
[43] Toratani S, Tani R, Kanda, et al. Photodynamic therapy using photofrin and excimer dye laser treatment for superficial oral squamous cell carcinomas with long-term follow up[J]. Photodiagnosis Photodyn Ther, 2016,14:104-110.
pmid: 26747657
[44] Karakullukcu B, van Oudenaarde K, Copper MP, et al. Photodynamic therapy of early stage oral cavity and oropharynx neoplasms: an outcome analysis of 170 patients[J]. Eur Arch Otorhinolaryngol, 2011,268(2):281-288.
doi: 10.1007/s00405-010-1361-5 pmid: 20706842
[45] Jerjes W, Upile T, Hamdoon Z, et al. Photodynamic therapy outcome for T1/T2 N0 oral squamous cell carcinoma[J]. Lasers Surg Med, 2011,43(6):463-469.
doi: 10.1002/lsm.21071 pmid: 21761416
[46] Durbec M, Cosmidis A, Fuchsmann C, et al. Efficacy and safety of photodynamic therapy with temoporfin in curative treatment of recurrent carcinoma of the oral cavity and oropharynx[J]. Eur Arch Otorhino-laryngol, 2013,270(4):1433-1439.
[47] Ikeda H, Tobita T, Ohba S, et al. Treatment outcome of photofrin-based photodynamic therapy for T1 and T2 oral squamous cell carcinoma and dysplasia[J]. Photodiagnosis Photodyn Ther, 2013,10(3):229-235.
pmid: 23993848
[48] Ikeda H, Ohba S, Egashira K, et al. The effect of photodynamic therapy with talaporfin sodium, a second-generation photosensitizer, on oral squamous cell carcinoma: a series of eight cases[J]. Photodia-gnosis Photodyn Ther, 2018,21:176-180.
[49] Yoshida T, Tokashiki R, Ito H, et al. Therapeutic effects of a new photosensitizer for photodynamic therapy of early head and neck cancer in relation to tissue concentration[J]. Auris Nasus Larynx, 2008,35(4):545-551.
pmid: 18242905
[50] Cerrati EW, Nguyen SA, Farrar JD, et al. The ef-ficacy of photodynamic therapy in the treatment of oral squamous cell carcinoma: a meta-analysis[J]. Ear Nose Throat J, 2015,94(2):72-79.
doi: 10.1177/014556131509400208 pmid: 25651350
[51] Elbers JBW, Al-Mamgani A, Paping D, et al. De-finitive (chemo)radiotherapy is a curative alternative for standard of care in advanced stage squamous cell carcinoma of the oral cavity[J]. Oral Oncol, 2017,75:163-168.
pmid: 29224815
[52] Jerjes W, Upile T, Radhi H, et al. Photodynamic therapy and end-stage tongue base cancer: short communication[J]. Head Neck Oncol, 2011,3:49.
pmid: 22152039
[53] Zhang YF, Zhang LL, Yang DG, et al. Treatment of oral refractory large area mucosal leukoplakia with CO2 laser combined with photodynamic therapy: case report[J]. Photodiagnosis Photodyn Ther, 2017,20:193-195.
doi: 10.1016/j.pdpdt.2017.10.006 pmid: 29037909
[54] Wang YY, Yang YD, Yang YC, et al. Surgery com-bined with topical photodynamic therapy for the treatment of squamous cell carcinoma of the lip[J]. Photodiagnosis Photodyn Ther, 2016,14:170-172.
doi: 10.1016/j.pdpdt.2016.04.008 pmid: 27102062
[55] Vander Poorten V, Meulemans J, Nuyts S, et al. Pos-toperative photodynamic therapy as a new adjuvant treatment after robot-assisted salvage surgery of recurrent squamous cell carcinoma of the base of tongue[J]. World J Surg Oncol, 2015,13:214.
doi: 10.1186/s12957-015-0630-6 pmid: 26179387
[56] Shi SR, Zhang LY, Zhu MQ, et al. Reactive oxygen species-responsive nanoparticles based on PEGlated prodrug for targeted treatment of oral tongue squa-mous cell carcinoma by combining photodynamic therapy and chemotherapy[J]. ACS Appl Mater Inter-faces, 2018,10(35):29260-29272.
[1] 郝福,宁毅,孙睿,郑晓旭. 口腔鳞状细胞癌中转化因子2β的表达及潜在的临床意义[J]. 国际口腔医学杂志, 2020, 47(2): 159-165.
[2] 薛伶俐,李雅冬. 经首次根治性手术治疗口腔鳞状细胞癌患者的生存相关影响因素分析[J]. 国际口腔医学杂志, 2020, 47(2): 166-174.
[3] 董云梅,陶艳,周瑜. 口腔黏膜癌变过程中血清生化标志物的研究进展[J]. 国际口腔医学杂志, 2020, 47(1): 43-50.
[4] 陈宏丽,杨敬,尹刚,李皓缘,乔燕. 锌指蛋白32在口腔鳞状细胞癌中的表达意义及对口腔鳞状细胞癌干细胞的影响[J]. 国际口腔医学杂志, 2019, 46(6): 631-639.
[5] 闫冰,骆献阳,谭迎赟,关丽梅,薛丽丽. 血清表面增强拉曼光谱应用于口腔鳞状细胞癌患者临床分期的研究[J]. 国际口腔医学杂志, 2019, 46(3): 277-281.
[6] 李群,关为群,张杨安,黄志超. 骨膜蛋白和p53在口腔白斑及鳞状细胞癌组织中的表达及意义[J]. 国际口腔医学杂志, 2019, 46(1): 5-11.
[7] 李媛媛,程斌,王韵. 长链非编码RNA lnc-p26090对口腔鳞状细胞癌细胞糖酵解及增殖的影响[J]. 国际口腔医学杂志, 2018, 45(6): 628-634.
[8] 王伊婷,何永文. 口腔鳞状细胞癌相关长链非编码RNA调控肿瘤细胞上皮-间充质转化的研究进展[J]. 国际口腔医学杂志, 2018, 45(6): 635-639.
[9] 方川,李雅冬. 微小RNA在口腔鳞状细胞癌中的研究进展[J]. 国际口腔医学杂志, 2018, 45(6): 646-651.
[10] 余芯乐, 郑军, 徐江, 曾妍. 口腔鳞状细胞癌患者唾液和血清中N-α-乙酰基转移酶10的水平及其临床意义[J]. 国际口腔医学杂志, 2018, 45(4): 391-395.
[11] 王琨,葛奕辰,崔博淼,苟雅萍,孙崇奎,龙敏,肖丽,英李燕. 端粒酶卡侯体蛋白1干扰慢病毒对口腔鳞状细胞癌细胞裸鼠致瘤作用的研究[J]. 国际口腔医学杂志, 2017, 44(1): 32-36.
[12] 刘盼1,多力昆?吾甫尔1,蔡志刚2,孙坚3. 维吾尔族口腔鳞状细胞癌患者中血清鳞状细胞癌抗原的表达研究[J]. 国际口腔医学杂志, 2016, 43(6): 645-650.
[13] 涂敏松1 李逸松2 代晓明2. DNA甲基化与口腔鳞状细胞癌的相关性研究进展[J]. 国际口腔医学杂志, 2016, 43(1): 79-.
[14] 李蓝江1 许冰莹1 杨春艳2 赵川3 田心2. 基质金属蛋白酶1、3和9基因多态性与云南汉族人群口腔鳞状细胞癌发病风险的相关性研究[J]. 国际口腔医学杂志, 2015, 42(6): 631-634.
[15] 孟令贤 班宇. 种植体表面去污联合手术疗法治疗种植体周围炎[J]. 国际口腔医学杂志, 2015, 42(4): 458-461.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
[1] 王涛. 外科优先序列治疗——正颌外科的发展热点之一及其误区[J]. 国际口腔医学杂志, 2020, 47(5): 497 -505 .
[2] 杨佩佩,杨羽晨,张强. 尼古丁对牙槽骨破骨细胞的作用及其机制的研究进展[J]. 国际口腔医学杂志, 2020, 47(5): 616 -620 .
[3] 薛晶. 邻面成形系统的发展和临床应用[J]. 国际口腔医学杂志, 2020, 47(6): 621 -626 .
[4] 尹圆圆,马华钰,李昕怡,徐静晨,柳汀,陈嵩,何姝姝. 小鼠正畸牙移动中牙周组织自噬相关基因表达的初步研究[J]. 国际口腔医学杂志, 2020, 47(6): 627 -634 .
[5] 陈青青,刘珍巧,王豫蓉. 穴位中频脉冲电刺激对下颌前伸大鼠咬肌改建的生理与生化研究[J]. 国际口腔医学杂志, 2020, 47(6): 635 -643 .
[6] 汪是琦,常雅琴,陈斌,谭葆春,泥艳红. 植骨术与植骨联用屏障膜在牙周再生治疗中临床疗效对比的系统评价与Meta分析[J]. 国际口腔医学杂志, 2020, 47(6): 644 -651 .
[7] 李静雅,税钰森,郭永文. 循环牵张应力影响人牙周膜细胞成骨分化机制的研究进展[J]. 国际口腔医学杂志, 2020, 47(6): 652 -660 .
[8] 吕辉,王华,孙雯. 辅助性T细胞17与牙周炎骨免疫[J]. 国际口腔医学杂志, 2020, 47(6): 661 -668 .
[9] 张心驰,吴炜. 颌面骨再生领域3D打印技术及应用材料的研究进展[J]. 国际口腔医学杂志, 2020, 47(6): 677 -685 .
[10] 吴洁林,高莺. 硬腭获取游离软组织移植物的应用进展[J]. 国际口腔医学杂志, 2020, 47(6): 686 -692 .